Novartis AG
NVSHealthcareNASDAQDrug Manufacturers - General · Last scanned Oct 26, 2026
Scan Results
Daily timeframeNovartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. At a $287.24B market cap, Novartis AG ranks as a mega-cap company within healthcare. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease.
Market Cap
$287.24B
Beta
0.47
P/E (TTM)
22.83
P/E (Fwd)
15.42
EPS (TTM)
$6.62
EPS (Fwd)
$9.80
ROE
30.3%
ROA
10.3%
Cash
$7.62B
Total Debt
$49.01B
Free CF
$11.90B
52W Change
17.0%
Annual Financials
Cash vs Debt
Where NVS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NVS finished 0.01% above its 150-day moving average ($150.19) and 0.06% above its 200-day moving average ($150.11). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NVS overbought or oversold?
At the October 20, 2026 close, NVS's RSI(14) was 62.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Novartis AG carries $49.01B in total debt against $7.62B in cash reserves — debt is roughly 6.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $11.90B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 30.3%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 10.2% further supports the picture of efficient asset utilization. Revenue has grown from $43.46B (2022) to $56.67B (2025), reflecting a 30% increase over the period.
The relatively low beta of 0.47 suggests NVS is a less volatile holding compared to the broader index. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NVS.